Lupin Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, approved by the Board of Directors on November 06, 2025. * Consolidated Performance (Q2 FY26): Revenue from operations stood at ₹7,047.51 crore, with a Net Profit after tax of ₹1,484.13 crore, marking a 72.6% increase compared to ₹859.48 crore in Q2 FY25. Basic Earnings Per Share (EPS) was ₹32.36. * Consolidated Performance (H1 FY26): Revenue from operations reached ₹13,315.85 crore, and Net Profit after tax was ₹2,706.29 crore, a 62.5% increase from ₹1,665.02 crore in H1 FY25. Basic EPS was ₹59.05. * Standalone Performance (Q2 FY26): Revenue from operations was ₹4,018.28 crore, with a Net Profit after tax of ₹1,357.35 crore, up significantly from ₹807.76 crore in Q2 FY25. Basic EPS (after exceptional items) was ₹29.72. * Standalone Performance (H1 FY26): Revenue from operations was ₹9,771.87 crore, and Net Profit after tax was ₹3,485.42 crore, a substantial increase from ₹1,696.94 crore in H1 FY25. Basic EPS (after exceptional items) was ₹76.32. * Corporate Actions: * The company disbursed a final dividend of ₹12 per equity share, totaling ₹548.10 crore, on August 14, 2025, as approved at the 43rd Annual General Meeting held on August 11, 2025. * Lupin transferred its Over the Counter ('OTC') and API R&D businesses in India to wholly-owned subsidiaries for ₹820.0 crore and ₹18.0 crore respectively, resulting in a gain of ₹658.96 crore and ₹3.72 crore. * During Q2 FY26, Nanomi B.V. agreed to acquire 100% share capital of VISUfarma B.V. for Euro 190.0 million, pending regulatory approval. * 41,745 equity shares were allotted during the quarter upon the exercise of vested stock options under ESOPs.
